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The Canadian Childhood Nephrotic Syndrome
(CHILDNEPH) Project: overview of design and
methods
Susan Samuel1*, Shannon Scott2, Catherine Morgan2, Allison Dart3, Cherry Mammen4, Rulan Parekh5,
Alberto Nettel-Aguirre1, Allison Eddy4, Rachel Flynn2, Maury Pinsk2, Andrew Wade1, Steven Arora6,
Geneviève Benoit7, Martin Bitzan8, Robin Erickson9, Janusz Feber10, Guido Filler11, Pavel Geier10, Colette Girardin12,
Silviu Grisaru1, James Tee13, Kyle Kemp1 and Michael Zappitelli8

Abstract
Background: Nephrotic syndrome is a commonly acquired kidney disease in children that causes significant
morbidity due to recurrent episodes of heavy proteinuria. The management of childhood nephrotic syndrome is
known to be highly variable among physicians and care centres.
Objectives: The primary objective of the study is to determine centre-, physician-, and patient-level characteristics
associated with steroid exposure and length of steroid treatment. We will also determine the association of dose
and duration of steroid treatment and time to first relapse as a secondary aim. An embedded qualitative study
utilizing focus groups with health care providers will enrich the quantitative results by providing an understanding
of the attitudes, beliefs and local contextual factors driving variation in care.
Design: Mixed-methods study; prospective observational cohort (quantitative component), with additional
semi-structured focus groups of healthcare professionals (qualitative component).
Setting: National study, comprised of all 13 Canadian pediatric nephrology clinics.
Patients: 400 patients under 18 years of age to be recruited over 2.5 years.
Measurements: Steroid doses for all episodes (first presentation, first and subsequent relapses) tracked over course
of the study. Physician and centre-level characteristics catalogued, with reasons for treatment preferences
documented during focus groups.
Methods: All patients tracked prospectively over the course of the study, with data comprising a prospective
registry. One focus group at each site to enrich understanding of variation in care.
Limitations: Contamination of treatment protocols between physicians may occur as a result of concurrent focus
groups.
Conclusions: Quantitative and qualitative results will be integrated at end of study and will collectively inform
strategies for the development and implementation of standardized evidence-based protocols across centres.
Keywords: Nephrotic syndrome, Cohort study, Practice variation, Qualitative methods
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Abrégé
Contexte: Le syndrome néphrotique est une néphropathie fréquente chez l’enfant, qui cause une morbidité
considérable en raison de la récurrence d’épisodes de protéinurie importante. La gestion du syndrome néphrotique
de l’enfant varie énormément d’un médecin et d’un centre de soins à l’autre.
Objectifs: L’objectif principal de cette étude est de déterminer les caractéristiques associées à l’exposition et la
durée du traitement aux stéroïdes, liées au centre, au médecin et au patient. En deuxième lieu, nous déterminerons
la corrélation entre la dose et la durée du traitement aux stéroïdes, puis la durée avant la première rechute. À cette
étude s’ajoutera une étude qualitative avec des groupes de discussion composés de professionnels de la santé qui
viendra enrichir les résultats quantitatifs en favorisant une meilleure compréhension des attitudes, des croyances et
des facteurs contextuels locaux qui entraînent des variations dans les soins.
Type d’étude: Une étude méthodologique mixte; étude d’observation de cohorte prospective (composante
quantitative), combinée avec des groupes de discussion semi-structurés composés de professionnels de la santé
(composante qualitative).
Contexte/Échantillon: Étude nationale, constituée des 13 cliniques canadiennes de néphrologie pédiatrique.
Participants: 400 patients âgés de moins de 18 ans, à recruter sur une période de 2,5 années.
Mesures: Suivi des doses de stéroïdes pour chacun des épisodes (première présentation, première rechute et
suivantes), tout au long de l’étude. Catalogage des caractéristiques liées au médecin ou au centre, et attestation des
raisons justifiant les préférences de traitement au cours des séances avec les groupes de discussion.
Méthodes: Tous les patients suivis de manière prospective dans le cadre de l’étude, dont les données constituent
un registre prospectif. Un groupe de discussion à chaque endroit, afin d’enrichir la compréhension des variations
dans les soins.
Limites de l’étude: La contamination des protocoles de traitement entre les médecins peut se produire en raison
de la tenue simultanée de groupes de discussions.
Conclusions: Les résultats quantitatifs et qualitatifs seront intégrés à la fin de l’étude et permettront de mettre en place
des stratégies de développement et de mise en œuvre de protocoles normalisés et fondés sur des données probantes.

What was known before
Management of childhood nephrotic syndrome is variable
between physicians and nephrology centres.
What this study adds
This is the first national, Canadian, population-based
evaluation of treatment of children with nephrotic syndrome. The study will provide novel information regarding factors driving treatment variation and how variation
affects patient outcomes.
Background
Childhood nephrotic syndrome, typically characterized by
recurrent episodes of heavy proteinuria and oedema, [1] is
one of the most common chronic conditions treated by
paediatric nephrologists. Patients may experience significant morbidity from complications of the disease or
its treatment including severe oedema, infections, and
thromboembolism that often leads to frequent hospitalizations and utilization of health care services [2].
Steroids are the treatment of choice both for first presentation and for subsequent relapses of nephrotic syndrome [3-7]. Steroid treatment is supported by evidence

published in systematic reviews [8,9] and a recent international Clinical Practice Guideline [10]. Clinical response
to steroids is the most important predictor of clinical outcome and prognosis [6].
Relapses of proteinuria are common in nephrotic syndrome and require multiple courses of steroid therapy.
Relapse risk is tightly linked to cessation of steroids (i.e.
when steroids are stopped, the likelihood of a relapse increases). Therefore, steroid treatment duration is a key
determinant of patient outcomes including treatment
and prevention of relapses and also steroid toxicity [11].
Although the current approach to treatment is based
on several seminal studies, [4,12,13] patient management
(choice of drugs, doses and duration) is known to be highly
variable between physicians and care centres [14,15]. A
better understanding of the factors driving this variation
will impact the design of future clinical trials evaluating
optimal duration of steroid therapy to minimize relapses
and toxicity.
Recently, treatment recommendations using the best
available evidence for effective treatments for nephrotic
syndrome were published in the Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis
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Clinical Practice Guideline [10]. In a physician survey of
practice patterns, we found differences between reported
practice and best evidence in the treatment of childhood
nephrotic syndrome, and specifically in the duration of
steroid therapy for first presentation of nephrotic syndrome [16]. Although, our survey was conducted prior to
release of the Guideline, it is vital to understand what
hinders and what facilitates the translation of Guideline
recommendations into routine clinical practice, and
these findings will also provide valuable insight into any
research conducted in this area.
We hypothesize that physician and centre factors will
play an important role in determining variation of steroid dosing for children with nephrotic syndrome. We
propose to use a mixed methods design with both quantitative and qualitative components to study this problem [17]. The larger study is quantitative and has a
longitudinal cohort design, while a qualitative study is
embedded within the larger study to provide a deeper
understanding of the complex and multi-level processes
that lead to the variation in practice. In this article, we
provide details regarding our study, the Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project, the
team, and supporting infrastructure. See Figure 1 for an
overview of the study.

Methods
Infrastructure and team

We applied the Knowledge to Action Cycle, an established
framework for knowledge translation, to the management
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of childhood nephrotic syndrome [18,19]. Using this
framework, we engaged decision-makers and end-users
(mainly paediatric nephrologists) in the research process
by first setting priorities and identifying key research questions. These same individuals will also assist us in the
interpretation and dissemination of results.
Our preparatory work was conducted within the
Canadian Kidney Knowledge Translation and Generation
Network (CANN-NET; www.cann-net.ca), a national initiative funded by the Canadian Institutes of Health Research (CIHR) linking kidney researchers, knowledge
translation specialists, and knowledge users to ensure best
practice in nephrology. CANN-NET has a Paediatrics
Committee, with broad representation from Canadian
paediatric nephrology centres, which is dedicated to promoting research, knowledge translation and best practices
in paediatric nephrology. Following a survey of Canadian
paediatric nephrologists in 2011, the Committee recognized
the importance of knowledge generation and translation in
childhood nephrotic syndrome. The CHILDNEPH Project
was formed in response to this identified need and brings
together researchers and knowledge users in paediatric
nephrology utilizing national supporting infrastructure.
The Canadian Association of Paediatric Nephrologists
(CAPN; www.capneph.ca) has supported our work by
allowing us to engage the wider CAPN membership
through study updates at semi-annual meetings. All 13
academic paediatric nephrology centres in Canada have
agreed to participate (Table 1), with site investigators
identified to ensure nationwide success of the study.

Figure 1 Overview of the Canadian Childhood Nephrotic Syndrome Project. KT: knowledge translation.
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Table 1 CHILDNEPH participating sites
Participating Site (Hospital)

City

Alberta Children’s Hospital

Calgary

Montreal Children’s Hospital

Montreal

Stollery Children’s Hospital

Edmonton

Children’s Hospital

Winnipeg

BC Children’s Hospital

Vancouver

SickKids Hospital

Toronto

Royal University Hospital

Saskatoon

IWK Health Centre

Halifax

Centre Hospitalier Universitaire Sainte-Justine

Montreal

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke

McMaster Children’s Hospital

Hamilton

Children’s Hospital of Eastern Ontario

Ottawa

Children’s Hospital, London Health Sciences Centre

London

Study design

We will use a mixed methods study as outlined by Creswell
and Plano Clark [17]. Institutional ethics approval will
be obtained for each participating site. We will conduct
a national prospective longitudinal observational cohort
study of children with nephrotic syndrome to obtain
data about the different doses and durations of steroid
treatments using a multi-level model analytic approach.
We will also evaluate the effect of variation in steroid
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treatment on patient outcome (time to first relapse). A
supplementary embedded qualitative study utilizing
health care provider focus groups will enrich the quantitative results by providing an understanding of the attitudes,
beliefs, and local contextual factors driving variation in care.
The studies (3-year quantitative and 1-year qualitative) will
be conducted concurrently. Upon study completion, we will
use convergent parallel mixed methods analytic approach
(both quantitative and qualitative data are collected and
analysed during the same phase of research, with the two
sets of results merged later for an overall interpretation)
[17] to compare qualitative and quantitative data across
centre-, physician-, and patient-level attributes (Figure 2).
Quantitative study
Study period and subject selection

Site-specific patient identification protocols will be developed to ensure all patients are screened for eligibility. The
enrolment period will last 2.5 years and the observation
period will continue for an additional 6 months thereafter.
The developed inclusion criteria balance the need to
maximize sample size, while minimizing individual contamination from prior treatments:
a) A child upon first presentation of nephrotic
syndrome who meets the following criteria: age: 1
to ≤18 years, oedema present, proteinuria (≥3+ on

Figure 2 Integration of qualitative and quantitative components of CHILDNEPH Project - Depiction of how the quantitative and
qualitative components of the project will be complementary in answering research questions.
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dipstick, ≥3 g/L on urinalysis or urine protein to
creatinine ratio [UP/C] ≥200 mg/mmol), serum
albumin ≤25 g/L, and no prior treatment with
steroids for nephrotic syndrome.
b) A child with an established diagnosis of idiopathic
childhood nephrotic syndrome who presents at the
beginning of either a first or second relapse (defined
as proteinuria ≥3+ on dipstick, ≥3 g/L on urinalysis
or UP/C ≥200 mg/mmol for 3 consecutive days, after
remission attained from prior treatment with
steroids, during enrolment period prior to start of
steroid-sparing agents).
Patients will be excluded if they meet one of the following criteria either at enrolment or during the course
of study:
a) Nephrotic syndrome in association with known
disease entity (e.g. lupus, malignancy).
b) Reduced serum C3 concentration.
c) Steroid-resistant patients will be excluded from the
final analysis (see below), but data will be entered
into the registry for ongoing follow-up.
Defining an exclusion criterion after enrolment is
necessary since current practice assumes that all patients
are ‘steroid sensitive’ at first presentation. As mentioned
above, a failure to induce complete remission of proteinuria defines steroid resistance. However, the protocol of this study will not define steroid resistance but
rather allow clinicians to follow their local operational
definitions.
Outcomes

Our primary outcome of interest is cumulative steroid
exposure (in mg/m2 prednisone equivalents) per episode.
An episode is defined as time from start of full dose daily
steroid therapy (60 mg/m2 or 2 mg/kg up to a maximum
dose of 60 mg/day) to either (i) cessation of steroids or (ii)
re-start of full-dose steroids in steroid-dependent patients
and is characterized either as first presentation or relapse.
We will examine: a) total dose received per episode; and
b) average daily dose per episode. This outcome definition
is consistent with measures of steroid exposure used in
prior studies conducted in Europe and Canada [7,20].
Expressing steroid exposure per unit time allows for the
comparison of patients with variable follow-up times (subjects recruited in the beginning versus at the end of a fixed
study period). We are evaluating steroid prescription per
episode as opposed to cumulative steroid exposure over a
specified observation interval because our primary aim is
to study determinants of variability in steroid prescription
for episodes of proteinuria rather than patient outcomes
(toxicity, frequency of relapses) related to cumulative
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exposure of steroids. The secondary outcome is the length
of episode in days, with daily versus alternate day therapy
taken into account. It is also important to note that we will
be capturing ‘prescribed steroids’ or ‘steroids taken as reported by family’. We will not be monitoring adherence
using pill counts, tracking of prescription refills or other
methods due to feasibility constraints. Nevertheless, we
will monitor adherence based on self- or parent-report as
a percentage of total prescribed medication ‘as taken’ and
this proportion will be used in adjusted analyses as
appropriate.
The following outcomes will be collected for descriptive
purposes: relapse rate, choice of steroid-sparing agent
stratified by clinical indication (frequently relapsing/
steroid-dependent/other), relapse rate prior to kidney
biopsy, and reasons for kidney biopsy. The following
outcomes will be used to measure complications of steroid treatment: anthropometric changes during observation period (age- and sex-specific standard-deviation
scores (z-scores) for height, weight, and body mass
index [BMI]), hypertension (≥95th percentile) during the
observation period and requirement for and duration of
antihypertensive therapy, and external manifestations of
steroid toxicity evident during semi-annual study visits
(cushingoid facies, hypertrichosis, cataracts, striae, acne)–
the definitions of which are similar to those observed in
prior nephrotic syndrome dosing studies [4].
Main determinant and exposure variables

We will study centre-, physician-, and patient-level variables as potential determinants of steroid exposure both
by cumulative dose and length of treatment. Centre-level
variable include ‘use of standardized protocols [yes/no]’.
Physician-level variables of interest include location of
nephrology fellowship training (Canadian and nonCanadian) and years in practice, both shown to significantly impact variability in practice patterns [16]. The
following patient-level variables will be used: age, gender, ethnicity, hematuria at presentation, estimated glomerular filtration rate (GFR) at presentation.
Study time points

Our study data points will follow the clinical course of
each patient. Children will be treated with steroids at each
episode. Study time points have been chosen to balance
the need to collect the required exposure and outcome
variables with the desire to minimize study visits. They
will be collected using standardized case report forms and
include: 1) study entry; 2) beginning of all subsequent relapses; 3) end of first episode and end of all subsequent relapses; 4) biannual study visits; 5) start of steroid-sparing
agents; 6) kidney biopsy; and 7) study-end visit. Physician
assessments will be performed at the following study
points: study entry, biannual study visits, study end.
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Data collection strategy

Data collected at study entry are a part of routine clinical care and include demographic information, height,
weight, blood pressure, blood test results (C3, albumin,
cholesterol if available), urine protein values by dipstick
(or urine protein to creatinine ratio), and medical history.
Details concerning the steroid prescription (including dose
and duration of initial dose and taper) will be collected at
entry and at all subsequent episodes. Data for study points
at the beginning and end of all relapses, start of steroidsparing agents, and kidney biopsy will be obtained using
one or all of the following methods: chart review, review of
patient log books of daily urine protein measurements and
steroid dose given (part of clinical routine), and phone calls
to family to confirm details of steroid prescription received.
Analysis

We will use mixed effects models with fixed effects for
centre, physician, and patient characteristics and random
effects to account for physicians clustering within centre,
patients clustering within physician, and episodes clustering within patients to study the association between selected exposures and outcomes (total per episode, average
dose per episode and length of steroid exposure). We will
describe all additional outcomes of interest by centre- and
patient-level variables. Association between cumulative
steroid exposure per unit time during first presentation
and time to first relapse will be determined using time-toevent analyses. We will account for potential collinearity
of centre and physician level variables with steroid exposure in our multi-level models.
Sample size and power considerations

Based on an estimate of 150 new Canadian paediatric
patients with nephrotic syndrome per year, a consent rate
of 72%, [21] an average relapse rate of one per year, and an
estimated drop out of 10% (due to loss to follow-up or
steroid resistance), we estimate an enrolment of at least
394 patients over a period of 2.5 years. These 394 patients
will yield between 394 and 650 observations (episode at
entry plus one additional relapse for approximately 70% of
all participants during the observation period). There is no
simple analytic formula to calculate required sample size
for mixed effects model analysis with three random effects
(physicians within centre, patients within physicians and
episodes within patients). Given the expected sample of
394 subjects and a total of 8 explanatory variables plus 3
random effects (estimated as parameters in the model),
our analysis will comply with the guideline of 10 observations (at the unit of analysis level) per variable [22].
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and local factors driving variation in care not captured by
quantitative approaches. Factors and interplay between
factors in clinical decision-making may involve physicians’
training and their familiarity with the evidence base, practice environment, and unique patient case scenarios. Theoretically grounded in the Ottawa Model of Research Use,
[23] a knowledge translation model, we will conduct focus
groups at participating sites with health professionals caring for these patients to probe for reasons for the variation
of steroid protocols used. Eight focus groups (4–6 participants per group) will be conducted, each lasting 60 minutes. Focus group participants will be identified by local
site investigator and will include physicians, nurses and
pharmacists who are involved nephrotic syndrome treatment at that site. Focus group questions are based upon
the six components of the Ottawa Model of Research Use
(innovation, potential adopters, practice environment,
interventions, adoption, and outcomes) and employ the
same multi-level framework as the quantitative study
(centre-, physician-, patient-level). We will group study
sites that within geographic proximity (e.g. all Quebec
sites). In centres where there are only one or two individuals managing nephrotic syndrome, we will do telephone interviews using a modified interview guide. This
data will be key for knowledge translation and dissemination strategies at the end of study.
Overview of qualitative data analysis

Qualitative data collection and analysis will proceed
concurrently. The inductive analysis will occur in three
phases: coding, categorizing, and developing themes [24].
Data analysis will be managed using the ‘NVIVO’ software
package (http://www.qsrinternational.com). To minimize
potential bias, the initial coding and analysis of the qualitative data (reviewing focus group transcripts) will be performed by members of the qualitative team who are not
participating in the initial quantitative analysis. All investigators will be involved in the final stages of analysis
as de-briefers to provide credibility to the findings. All
methodological decisions and insights will be documented in an audit trail [24,25].
Project and data management

The study will be supervised and managed by a coordinating centre in Calgary, Alberta. All de-identified patient
and physician data will be entered into an online multicentre database (REDCap™) which allows users to build
databases securely for the purposes of research, particularly longitudinal cohort studies.
Integration of quantitative and qualitative studies

Qualitative study

The embedded qualitative study will enrich the quantitative results by providing details regarding attitudes, beliefs,

A convergent mixed methods analytic approach will be
used to compare the results obtained in both the quantitative and qualitative analysis. Using matrices of the
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hierarchies of centre-, physician- and patient-levels, the
explanatory quantitative variables and themes arising
from the qualitative study (e.g. existence of standardized
protocols in each centre, age and training background
of the physician, patient’s age and ethnicity) at each
level will be compared for their congruence.
Funding sources

This project is funded by the CIHR Institute for Nutrition
Metabolism and Diabetes (start-up funds, grant number
PNI-134070), and the University of Calgary Roy Vi Baay
Chair for Kidney Research.

Discussion
The CHILDNEPH Project will address two important unanswered questions in childhood nephrotic syndrome–(i)
Who and what drives variability in care? and (ii) Does the
variability in care influence outcomes? We will also establish a national longitudinal cohort with a web-based collection of patient data. The study data and results will be
used to systematically evaluate clinical care and outcomes,
to help standardize care across centers and to evaluate the
effects of such efforts on patient outcomes. We will also
demonstrate the feasibility of identifying patients across
Canada to conduct well-designed RCTs for optimal steroid
therapy and steroid-sparing agents for nephrotic syndrome, while determining what barriers may exist in enrolling such patients.
Since childhood nephrotic syndrome meets the CIHR
definition of a ‘rare’ disease (affects one person out of
2,000 or fewer), [26] almost no single centre or region in
Canada has a sufficient number of patients to produce
generalizable knowledge regarding effective treatments.
First arising in the paediatric oncology community in
the 1950s and improving paediatric oncology outcomes
from almost universally fatal to a current survival rate of
82%, [27] multi-centre collaborative clinical research
networks can overcome this barrier and improve health
outcomes of children with rare diseases. Another example
of a collaborative network includes the ImproveCareNow
network (https://improvecarenow.org) for paediatric inflammatory bowel disease (IBD). With 25% of American
paediatric gastroenterologists and 34 sites, the group has
seen remission rates for Crohn’s disease and colitis improve from 49% to 78% in just 5 years [28-30]. Each of
these sub-specialty areas found significant improvements
through participation in the network, adherence to common ‘model’ care guidelines, and examination of the influence of practice variation on patient outcomes. The
CHILDNEPH study will be foundational for the establishment of such a network for childhood nephrotic syndrome
and for our future work in this area.
Variations in clinical practice may exist as a result of
uncertainty in evidence or a lack of implementation
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strategies for existing clinical practice guidelines, the latter
of which can be hindered at various levels - patient, physician, and health system [19]. As part of the knowledge
translation activities for the CHILDNEPH project, we
will develop an active dissemination and implementation strategy to help promote the uptake of clinical
practice guidelines for the management of childhood
nephrotic syndrome and may include the development
of clinical pathways. This combination of information
regarding factors driving practice variation and knowledge translation strategies will increase the likelihood
of uptake of guideline recommendations.
Data from this study will provide us with information
to design a clinical trial to determine the impact of
cumulative steroid exposure at first presentation on time
to first relapse and frequency of relapses. The duration
of steroid therapy for first presentation of nephrotic syndrome is still debated within the literature; [31,32] thus,
the KDIGO Guideline recommends a wide interval for
steroid therapy (daily for 6 weeks followed by 2–5 months
of alternate day treatment). Our study will help us understand why physicians choose one steroid duration over another, which will identify barriers to adopting common
protocols for steroid therapy. Furthermore, data regarding
use and response to steroids will assist us in designing a
clinical trial to determine the best steroid-sparing agent in
frequently relapsing and steroid-dependent patients.
One significant source of bias in our study is due to
physician participation in the focus groups as we are
concurrently conducting the longitudinal observational
cohort study. We acknowledge that contamination of
treatment protocols may occur between physicians in one
centre and centers may take measures to standardize care
after the focus groups. We will monitor for this trend in
the data.
In summary, this national longitudinal cohort study
will generate novel data regarding determinants of
variation in care and the effects of variation on patient
outcomes. The study will integrate clinical care and
patient-oriented research programs, similar to other collaborative clinical care and research initiatives in childhood cancer and childhood inflammatory bowel disease
[27,29]. Our future directions will include design and conduct of RCTs to address critical knowledge gaps related to
the treatment of nephrotic syndrome.
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